原研机构 |
非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)临床1期 |
特殊审评- |
开始日期2024-09-02 |
申办/合作机构 正序(上海)生物科技有限公司 [+1] |
开始日期2024-04-18 |
申办/合作机构 |
开始日期2024-03-19 |
申办/合作机构 正序(上海)生物科技有限公司 [+1] |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
镰状细胞血症 | 临床1期 | 中国 | 2024-09-02 | |
β地中海贫血 | 临床1期 | 中国 | 2024-04-18 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 6 | 廠鑰鏇簾衊齋鬱願製壓(築積遞膚觸觸鏇觸壓築) = All participants had ≥1 adverse event (AE) of Grade 3 or 4 severity (including laboratory-based AEs). The most three common Grade 3 or 4 AEs were neutrophil count decreased (100%), platelet count decreased (100%), and white blood cell decreased (100%). Most AEs were commonly observed after myeloablative busulfan conditioning and no AEs were reported as related to CS-101 in the 6 patients. 範鑰糧範蓋願觸願築築 (獵壓簾膚顧鏇衊襯簾醖 ) 更多 | 积极 | 2024-12-09 | |||
N/A | - | 3 | 鑰壓構選壓糧壓窪夢獵(觸鏇蓋製製範艱鹹糧夢) = No SAEs were reported up to the cut-off date 齋壓艱遞襯淵窪膚構鑰 (淵糧壓簾鏇網顧窪積鏇 ) 更多 | 积极 | 2024-05-14 | ||
临床1期 | 1 | 淵獵糧積構選憲醖廠構(築鑰築網製鏇獵簾構鹹) = 窪鬱膚鏇積積願餘繭選 積衊範醖壓簾窪築齋鬱 (夢願選繭艱憲獵鑰膚獵 ) | 积极 | 2024-01-08 |